Retrospective analysis of the relationship between elevated plasma levels of TXNIP and carotid intima-media thickness in subjects with impaired glucose tolerance and early Type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 109, Issue 2, 2015, Pages 372-377

  Zhao, Yongcai ^a   Li, Xinsheng ^a   Tang, Shiling ^a  

^a CANGZHOU CENTRAL HOSPITAL   (China)

Author keywords

Carotid intima media thickness; Glucose metabolism disorders; Glucose tolerance test; TXNIP; Type 2 diabetes mellitus; Ultrasonography

Indexed keywords

THIOREDOXIN INTERACTING PROTEIN; VASCULAR CELL ADHESION MOLECULE 1; CARRIER PROTEIN; GLUCOSE BLOOD LEVEL; THIOREDOXIN; TXNIP PROTEIN, HUMAN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CLINICAL FEATURE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; BLOOD; COMMON CAROTID ARTERY; COMPLICATION; ECHOGRAPHY; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; METABOLISM; MIDDLE AGED;

ATHEROSCLEROSIS; BLOOD GLUCOSE; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; THIOREDOXINS;

EID: 84937971306     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.05.028     Document Type: Article

References (31)

1. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005, 366(9493):1279-1289.
2. Wackers F.J., Young L.H., Inzucchi S.E., Chyun D.A., Davey J.A., Barrett E.J., et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004, 27(8):1954-1961.
3. Shin J.Y., Lee H.R., Lee D.C. Increased arterial stiffness in healthy subjects with high-normal glucose levels and in subjects with pre-diabetes. Cardiovasc Diabetol 2011, 10:30.
4. Persson J., Formgren J., Israelsson B., Berglund G. Ultrasound-determined intima-media thickness and atherosclerosis. Direct and indirect validation. Arterioscler Thromb 1994, 14(2):261-264.
5. Mancini G.B., Dahlof B., Diez J. Surrogate markers for cardiovascular disease: structural markers. Circulation 2004, 109(25 [Suppl 1]):SIV22-SIV30.
6. Zalba G., Beloqui O., San Jose G., Moreno M.U., Fortuno A., Diez J. NADPH oxidase-dependent superoxide production is associated with carotid intima-media thickness in subjects free of clinical atherosclerotic disease. Arterioscler Thromb Vasc Biol 2005, 25(7):1452-1457.
7. Spence J.D., Eliasziw M., DiCicco M., Hackam D.G., Galil R., Lohmann T. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke 2002, 33(12):2916-2922.
8. Djaberi R., Schuijf J.D., Jukema J.W., Rabelink T.J., Stokkel M.P., Smit J.W., et al. Increased carotid intima-media thickness as a predictor of the presence and extent of abnormal myocardial perfusion in Type 2 diabetes. Diabetes Care 2010, 33(2):372-374.
9. Jarasuniene D., Simaitis A. Oxidative stress and endothelial dysfunction. Medicina (Kaunas) 2003, 39(12):1151-1157.
10. Sorescu D., Weiss D., Lassegue B., Clempus R.E., Szocs K., Sorescu G.P., et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002, 105(12):1429-1435.
11. Rochette L., Zeller M., Cottin Y., Vergely C. Diabetes, oxidative stress and therapeutic strategies. Biochim Biophys Acta 2014, 1840(9):2709-2729.
12. Munzel T., Sinning C., Post F., Warnholtz A., Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008, 40(3):180-196.
13. Patwari P., Higgins L.J., Chutkow W.A., Yoshioka J., Lee R.T. The interaction of thioredoxin with TXNIP. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem 2006, 281(31):21884-21891.
14. Yoshihara E., Masaki S., Matsuo Y., Chen Z., Tian H., Yodoi J. Thioredoxin/TXNIP: redoxisome, as a redox switch for the pathogenesis of diseases. Front Immunol 2014, 4:514.
15. Yoshioka J., Lee R.T. Thioredoxin-interacting protein and myocardial mitochondrial function in ischemia-reperfusion injury. Trends Cardiovasc Med 2014, 24(2):75-80.
16. Schulze P.C., Yoshioka J., Takahashi T., He Z., King G.L., Lee R.T. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 2004, 279(29):30369-30374.
17. Chong C.R., Chan W.P., Nguyen T.H., Liu S.F., Procter N.E.K., Ngo D.T., et al. Thioredoxin-interacting protein: pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and diabetes. Cardiovasc Drugs Ther 2014, 28(4):347-360.
18. Berk B.C. Novel approaches to treat oxidative stress and cardiovascular diseases. Trans Am Clin Climatol Assoc 2007, 118:209-214.
19. Perrone L., Devi T.S., Hosoya K., Terasaki T., Singh L.P. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol 2009, 221(1):262-272.
20. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation 2006, 1-50. World Health Organization, World Health Organization, Geneva.
21. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007, 25(9):1751-1762.
22. Hunt K.J., Williams K., Rivera D., O'Leary D.H., Haffner S.M., Stern M.P., et al. Elevated carotid artery intima-media thickness levels in individuals who subsequently develop Type 2 diabetes. Arterioscler Thromb Vasc Biol 2003, 23(10):1845-1850.
23. Wagenknecht L.E., D'Agostino R.B., Haffner S.M., Savage P.J., Rewers M. Impaired glucose tolerance, Type 2 diabetes, and carotid wall thickness: the insulin resistance atherosclerosis study. Diabetes Care 1998, 21(11):1812-1818.
24. Yamasaki Y., Kawamori R., Matsushima H., Nishizawa H., Kodama M., Kubota M., et al. Asymptomatic hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery. Diabetologia 1995, 38(5):585-591.
25. Sozer V., Himmetoglu S., Korkmaz G.G., Kaya S., Aydin S., Yumuk V., et al. Paraoxonase, oxidized low density lipoprotein, monocyte chemoattractant protein-1 and adhesion molecules are associated with macrovascular complications in patients with Type 2 diabetes mellitus. Minerva Med 2014, 105(3):237-244.
26. Mokini Z., Marcovecchio M.L., Chiarelli F. Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. Diabetes Res Clin Pract 2010, 87(3):313-321.
27. World C.J., Yamawaki H., Berk B.C. Thioredoxin in the cardiovascular system. J Mol Med (Berl) 2006, 84(12):997-1003.
28. Kluz J., Kopec W., Jakobsche-Policht U., Adamiec R. Circulating endothelial cells, endothelial apoptosis and soluble markers of endothelial dysfunction in patients with systemic lupus erythematosus-related vasculitis. Int Angiol 2009, 28(3):192-201.
29. Ceriello A., Quagliaro L., Piconi L., Assaloni R., Da Ros R., Maier A., et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004, 53(3):701-710.
30. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105(9):1135-1143.
31. Sung H.J., Eskin S.G., Sakurai Y., Yee A., Kataoka N., McIntire L.V. Oxidative stress produced with cell migration increases synthetic phenotype of vascular smooth muscle cells. Ann Biomed Eng 2005, 33(11):1546-1554.